MBCI Stock Overview

MBCI fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Does not have a meaningful market cap ($78K)

Latest financial reports are more than a year old

Shares are highly illiquid

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

MabCure, Inc. Competitors

TC Biopharm (Holdings)

OTCPK:TCBP.Y

US$123.1k

Vaxxinity

OTCPK:VAXX

US$25.3k

NuCana

NasdaqCM:NCNA

US$254.4k

Vincerx Pharma

OTCPK:VINC

US$275.8k

Price History & Performance

Summary of share price highs, lows and changes for MabCure
Historical stock prices
Current Share Price	US$0.0001
52 Week High	US$0.0001
52 Week Low	US$0.000001
Beta	0
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	-97.83%
5 Year Change	-92.25%
Change since IPO	-99.99%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	MBCI	US Biotechs	US Market
7D	0%	-2.6%	3.9%
1Y	n/a	-12.1%	11.6%

Return vs Industry: Insufficient data to determine how MBCI performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how MBCI performed against the US Market.

Price Volatility

Is MBCI's price volatile compared to industry and market?
MBCI volatility
MBCI Average Weekly Movement	n/a
Biotechs Industry Average Movement	11.9%
Market Average Movement	8.1%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	4.2%

Stable Share Price: MBCI's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine MBCI's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2006	n/a	Jehu Thomas Hand	n/a

MabCure Inc., a development stage company, engages in developing and commercializing its proprietary antibody technology for the early detection of cancer, and for the creation of specific therapeutics against cancer. It owns a proprietary technology for the generation of monoclonal antibodies against desired antigens, such as cancer markers. The company was formerly known as Smartec Holdings, Inc. and changed its name to MabCure Inc. in January 2008 to reflect its new business plan.

MabCure, Inc. Fundamentals Summary

How do MabCure's earnings and revenue compare to its market cap?
MBCI fundamental statistics
Market cap	US$78.11k
Earnings (TTM)	-US$12.26m
Revenue (TTM)	US$500.00k

0.0x

P/S Ratio

0.0x

P/E Ratio

Is MBCI overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MBCI income statement (TTM)
Revenue	US$500.00k
Cost of Revenue	US$0
Gross Profit	US$500.00k
Other Expenses	US$12.76m
Earnings	-US$12.26m

Last Reported Earnings

Dec 31, 2011

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did MBCI perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/13 12:47
End of Day Share Price	2025/05/09 00:00
Earnings	2011/12/31
Annual Earnings	2011/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

MabCure, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.